- November 28, 2023
Sanacora, Wilkinson Receive $12.6M in Funding for Ketamine Study
- November 28, 2023Source: Proceedings of the National Academy of Sciences Perspective
Ketamine and the Neurobiology of Depression: Toward Next-generation Rapid-acting Antidepressant Treatments
- November 17, 2023Source: National Geographic
Ketamine Effectively Treats Depression. Do the Benefits Outweigh the Risks?
- September 13, 2023
Wilkinson, Rhee Awarded NIH Research Project Grants
- August 03, 2023Source: CNN
Nothing worked for her teenage son's depression, until his doctor suggested ketamine
- July 06, 2023Source: JAMA Psychiatry
The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents
Yale Depression Research Program
Operated jointly by the Yale University School of Medicine Department of Psychiatry and Connecticut Mental Health Center, the Yale Depression Research Program has, for over 30 years, been committed to advancing the treatment of depression. By engaging in studies that seek to elucidate the underlying neurobiology of depression, we are striving to improve our ability to diagnose and treat mood disorders.
Depression remains one of the most common and debilitating medical problems throughout the world. At the Yale Depression Research Program, we are committed to advancing our ability to understand, diagnose, and treat depression through innovative research.